Kamran Mahmood1, Bryan D Kraft2, Kristen Glisinski3, Matthew G Hartwig4, Nicole P Harlan2,5, Claude A Piantadosi2,5, Scott L Shofer2. 1. Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Duke University Medical Center, Durham, NC, USA. k.mahmood@duke.edu. 2. Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Duke University Medical Center, Durham, NC, USA. 3. Department of Medicine, Duke University Medical Center, Durham, NC, USA. 4. Division of Cardiovascular and Thoracic Surgery, Department of Surgery, Duke University Medical Center, Durham, NC, USA. 5. Center for Hyperbaric Medicine and Environmental Physiology, Department of Anesthesiology, Duke University Medical Center, Durham, NC, USA.
Abstract
BACKGROUND: Central airway stenosis (CAS) is common after lung transplantation and causes significant post-transplant morbidity. It is often preceded by extensive airway necrosis, related to airway ischemia. Hyperbaric oxygen therapy (HBOT) is useful for ischemic grafts and may reduce the development of CAS. METHODS: The purpose of this study was to determine whether HBOT could be safely administered to lung transplant patients with extensive necrotic airway plaques. Secondarily, we assessed any effects of HBOT on the incidence and severity of CAS. Patients with extensive necrotic airway plaques within 1-2 months after lung transplantation were treated with HBOT along with standard care. These patients were compared with a contemporaneous reference group with similar plaques who did not receive HBOT. RESULTS: Ten patients received HBOT for 18.5 (interquartile range, IQR 11-20) sessions, starting at 40.5 (IQR 34-54) days after transplantation. HBOT was well tolerated. Incidence of CAS was similar between HBOT-treated patients and reference patients (70% vs 87%, respectively; P=.34), but fewer stents were required in HBOT patients (10% vs 56%, respectively; P=.03). CONCLUSIONS: This pilot study is the first to demonstrate HBOT safety in patients who develop necrotic airway plaques after lung transplantation. HBOT may reduce the need for airway stent placement in patients with CAS.
BACKGROUND: Central airway stenosis (CAS) is common after lung transplantation and causes significant post-transplant morbidity. It is often preceded by extensive airway necrosis, related to airway ischemia. Hyperbaric oxygen therapy (HBOT) is useful for ischemic grafts and may reduce the development of CAS. METHODS: The purpose of this study was to determine whether HBOT could be safely administered to lung transplant patients with extensive necrotic airway plaques. Secondarily, we assessed any effects of HBOT on the incidence and severity of CAS. Patients with extensive necrotic airway plaques within 1-2 months after lung transplantation were treated with HBOT along with standard care. These patients were compared with a contemporaneous reference group with similar plaques who did not receive HBOT. RESULTS: Ten patients received HBOT for 18.5 (interquartile range, IQR 11-20) sessions, starting at 40.5 (IQR 34-54) days after transplantation. HBOT was well tolerated. Incidence of CAS was similar between HBOT-treated patients and reference patients (70% vs 87%, respectively; P=.34), but fewer stents were required in HBOT patients (10% vs 56%, respectively; P=.03). CONCLUSIONS: This pilot study is the first to demonstrate HBOT safety in patients who develop necrotic airway plaques after lung transplantation. HBOT may reduce the need for airway stent placement in patients with CAS.
Authors: H I Friedman; H I F Friedman; M Fitzmaurice; J F Lefaivre; T Vecchiolla; D Clarke Journal: Plast Reconstr Surg Date: 2006-06 Impact factor: 4.730
Authors: Harriet W Hopf; Jeffrey J Gibson; Adam P Angeles; James S Constant; John J Feng; Mark D Rollins; M Zamirul Hussain; Thomas K Hunt Journal: Wound Repair Regen Date: 2005 Nov-Dec Impact factor: 3.617
Authors: Gundeep S Dhillon; Martin R Zamora; Justus E Roos; Deirdre Sheahan; Ramachandra R Sista; Pieter Van der Starre; David Weill; Mark R Nicolls Journal: Am J Respir Crit Care Med Date: 2010-03-25 Impact factor: 21.405
Authors: David R Nunley; Anthony A Gal; J David Vega; Carl Perlino; Pauline Smith; E Clinton Lawrence Journal: Chest Date: 2002-10 Impact factor: 9.410
Authors: Caroline Van De Wauwer; Dirk Van Raemdonck; Geert M Verleden; Lieven Dupont; Paul De Leyn; Willy Coosemans; Philippe Nafteux; Toni Lerut Journal: Eur J Cardiothorac Surg Date: 2007-02-15 Impact factor: 4.191
Authors: Peter Kranke; Michael H Bennett; Marrissa Martyn-St James; Alexander Schnabel; Sebastian E Debus Journal: Cochrane Database Syst Rev Date: 2012-04-18
Authors: Anthony W Castleberry; Mathias Worni; Maragatha Kuchibhatla; Shu S Lin; Laurie D Snyder; Scott L Shofer; Scott M Palmer; Ricardo Pietrobon; R Duane Davis; Matthew G Hartwig Journal: Ann Thorac Surg Date: 2013-07-18 Impact factor: 4.330
Authors: Anna L Sander; Dirk Henrich; Claus M Muth; Ingo Marzi; John H Barker; Johannes M Frank Journal: Wound Repair Regen Date: 2009 Mar-Apr Impact factor: 3.617
Authors: Bryan D Kraft; Kamran Mahmood; Nicole P Harlan; Matthew G Hartwig; Laurie D Snyder; Hagir B Suliman; Scott L Shofer Journal: J Heart Lung Transplant Date: 2021-01-15 Impact factor: 10.247